Ernexa Therapeutics Inc.

What they do

Ernexa develops induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) therapies. Its lead candidate, ERNA-101, secretes IL-7 and IL-15 to target the tumor microenvironment in platinum-resistant ovarian cancer. It also has a preclinical candidate, ERNA-201, for autoimmune disorders like rheumatoid arthritis. The company is currently focused on IND-enabling activities and regulatory preparation.

Revenue drivers

• No commercial products — Ernexa has no approved products and has generated minimal revenue, primarily from grants or collaboration payments; revenue in 2024 was $582,000.
• Potential partnership/licensing — The company plans to seek strategic partnerships to co-develop or out-license therapeutic assets, but no revenue has been recognized from such arrangements.
• ERNA-101 and ERNA-201 — These are preclinical candidates with no revenue contribution; all current focus is on development rather than commercial sales.

Recent performance

In the year ended December 31, 2025, Ernexa reported a net loss of $14.1 million with revenue of $582,000, an improved loss from $44.5 million in 2024. Quarterly revenue was minimal, with $487,000 in Q3 2024 and $1,000 in Q4 2024. As of June 30, 2026, cash and equivalents were $5.0 million, with total assets of $6.3 million and shareholder equity of $3.2 million. Operating cash flow has been negative but improving, from -$23.5 million in 2021 to -$7.0 million in 2025.

Strategy

Ernexa's strategy is to advance ERNA-101 through IND-enabling studies and into a Phase 1 investigator-sponsored trial in platinum-resistant ovarian cancer, with a planned IND submission in 2026. The company is also developing ERNA-201 for autoimmune diseases and is participating in the Japan External Trade Organization acceleration program to explore collaborations in Japan. To raise non-dilutive capital, Ernexa is actively seeking partnerships and applying for research grants. A reverse stock split was effected in May 2026 to meet Nasdaq listing requirements.

Risks

• Going concern risk — The company states it will not have sufficient capital to fund operations for the next 12 months and may need to reduce expenses, file for bankruptcy, or cease operations if additional financing is not obtained.
• Preclinical stage risk — ERNA-101 and ERNA-201 are preclinical; failures in IND-enabling studies or clinical trials could delay or halt development.
• Dependence on in-licensed IP — The company relies on licensed technology from Factor Bioscience and has not yet resolved inventorship issues related to the MD Anderson patent application.
• Nasdaq listing compliance — The company received a delisting notice in March 2026 and may fail to meet minimum bid price or other listing requirements, potentially affecting liquidity.

Outlook

Management expects to complete IND-enabling studies and submit an IND for ERNA-101 in 2026, with a Phase 1 investigator-sponsored trial expected in the second half of 2026. Independent validation of ERNA-101 data in July 2026 is cited as strengthening confidence in the mechanism. The company continues to seek partnerships and grants to fund operations.